Neurologic Toxicities of Immunotherapy.
CAR T cell therapy
Checkpoint inihibitor
Encephalitis
Immune effector cell-associated neurotoxicity
Immunotherapy
Myasthenia gravis
Myositis
Neurotoxicity
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
1
1
2022
pubmed:
2
1
2022
medline:
5
1
2022
Statut:
ppublish
Résumé
Immunotherapy has revolutionized treatment of cancer over the past two decades. The antitumor effects of immunotherapy approaches are at the expense of growing spectrum of immune-related adverse events (irAEs) due to cross-reactivity between the tumor and normal host tissue. These adverse events can happen in any organ and range from mild to severe and even life-threatening conditions. While neurological irAEs associated with immune checkpoint inhibitors (CPIs) are rare, they pose a significant challenge in management as the clinical phenotypes are heterogenous and frequently necessitate cessation of therapy and systemic immune suppression and lead to transient functional decline. On the other hand, immune effector cell-associated neurotoxicity (ICANS) is common, frequently occurs in conjunction with cytokine release syndrome (CRS), and poses a significant clinical challenge to the development and widespread use of these effective therapies. Early recognition of these neurological syndromes, timely diagnosis, and thoughtful management are key for further clinical development of these effective therapies in cancer patients. Here, we describe clinical phenotypes of CPI-induced neurological complications and ICANS and discuss steps in clinical monitoring, diagnosis, and effective management.
Identifiants
pubmed: 34972978
doi: 10.1007/978-3-030-79308-1_18
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
417-429Informations de copyright
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Rogado, J., Sanchez-Torres, J. M., Romero-Laorden, N., et al. (2019). Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. European Journal of Cancer, 109, 21–27.
pubmed: 30682533
Fujii, T., Naing, A., Rolfo, C., & Hajjar, J. (2018). Biomarkers of response to immune checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 130, 108–120.
pubmed: 30196907
Dubey, D., David, W. S., Reynolds, K. L., et al. (2020). Severe neurological toxicity of immune checkpoint inhibitors: Growing Spectrum. Annals of Neurology, 87, 659–669.
pubmed: 32086972
Cuzzubbo, S., Javeri, F., Tissier, M., et al. (2017). Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. European Journal of Cancer, 73, 1–8.
pubmed: 28064139
Abramson, J. S., Palomba, M. L., Gordon, L. I., et al. (2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet, 396, 839–852.
pubmed: 32888407
pmcid: 32888407
Maude, S. L., Laetsch, T. W., Buechner, J., et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. The New England Journal of Medicine, 378, 439–448.
pubmed: 29385370
pmcid: 5996391
Munshi, N. C., Anderson, L. D., Jr., Shah, N., et al. (2021). Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. The New England Journal of Medicine, 384, 705–716.
pubmed: 33626253
Neelapu, S. S., Locke, F. L., Bartlett, N. L., et al. (2017). Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. The New England Journal of Medicine, 377, 2531–2544.
pubmed: 29226797
pmcid: 5882485
Schuster, S. J., Bishop, M. R., Tam, C. S., et al. (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. The New England Journal of Medicine, 380, 45–56.
pubmed: 30501490
Wang, M., Munoz, J., Goy, A., et al. (2020). KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. The New England Journal of Medicine, 382, 1331–1342.
pubmed: 32242358
pmcid: 7731441
Naing, A., Hajjar, J., Gulley, J. L., et al. (2020). Strategies for improving the management of immune-related adverse events. Journal for Immunotherapy of Cancer, 8.
Mendoza, T., Sheshadri, A., Altan, M., et al. (2020). Evaluating the psychometric properties of the immunotherapy module of the MD Anderson symptom inventory. Journal for Immunotherapy of Cancer, 8.
Hodi, F. S., O'Day, S. J., McDermott, D. F., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363, 711–723.
pubmed: 20525992
pmcid: 3549297
Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020). T-cell agonists in cancer immunotherapy. Journal for Immunotherapy of Cancer, 8.
Pan, P. C., & Haggiagi, A. (2019). Neurologic immune-related adverse events associated with immune checkpoint inhibition. Current Oncology Reports, 21, 108.
pubmed: 31776691
Maeda, O., Yokota, K., Atsuta, N., Katsuno, M., Akiyama, M., & Ando, Y. (2016). Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya Journal of Medical Science, 78, 119–122.
pubmed: 27019533
pmcid: 4767520
Kyi, C., Carvajal, R. D., Wolchok, J. D., & Postow, M. A. (2014). Ipilimumab in patients with melanoma and autoimmune disease. Journal for Immunotherapy of Cancer, 2, 35.
pubmed: 25349698
pmcid: 4207313
Weiss, M. D., Luciano, C. A., Semino-Mora, C., Dalakas, M. C., & Quarles, R. H. (1998). Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology, 51, 1738–1741.
pubmed: 9855537
Tsuchida, T., Saxton, R. E., Morton, D. L., & Irie, R. F. (1987). Gangliosides of human melanoma. Journal of the National Cancer Institute, 78, 45–54.
pubmed: 3467129
Sato, K., Akamatsu, H., Murakami, E., et al. (2018). Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer (Amsterdam, Netherlands), 115, 71–74.
Bomze, D., Hasan Ali, O., Bate, A., & Flatz, L. (2019). Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden. JAMA Oncology.
Algaeed, M., Mukharesh, L., Heinzelmann, M., & Kaminski, H. J. (2018). Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis. Neurology, 91, e1365–e13e7.
pubmed: 30275130
Makarious, D., Horwood, K., & Coward, J. I. G. (2017). Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. European Journal of Cancer (Oxford, England: 1990), 82, 128–136.
Lau, K. H., Kumar, A., Yang, I. H., & Nowak, R. J. (2016). Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle & Nerve, 54, 157–161.
Huh, S. Y., Shin, S. H., Kim, M. K., Lee, S. Y., Son, K. H., & Shin, H. Y. (2018). Emergence of myasthenia gravis with myositis in a patient treated with Pembrolizumab for Thymic Cancer. Journal of Clinical Neurology (Seoul, Korea), 14, 115–117.
Kimura, T., Fukushima, S., Miyashita, A., et al. (2016). Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Science, 107, 1055–1058.
pubmed: 27420474
pmcid: 4946722
Polat, P., & Donofrio, P. D. (2016). Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle & Nerve, 54, 507.
Kao, J. C., Liao, B., Markovic, S. N., et al. (2017). Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology, 74, 1216–1222.
pubmed: 28873125
pmcid: 5710300
Moslehi, J. J., Salem, J. E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018). Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet (London, England), 391, 933.
Jaretzki, A., 3rd, Barohn, R. J., Ernstoff, R. M., et al. (2000). Myasthenia gravis: Recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America. The Annals of Thoracic Surgery, 70, 327–334.
pubmed: 10921745
Brahmer, J. R., Lacchetti, C., & Thompson, J. A. (2018). Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. Journal of Oncology Practice/ American Society of Clinical Oncology, 14, 247–249.
Barrons, R. W. (1997). Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy, 17, 1220–1232.
pubmed: 9399604
Hunter, G., Voll, C., & Robinson, C. A. (2009). Autoimmune inflammatory myopathy after treatment with ipilimumab. The Canadian Journal of Neurological Sciences, 36, 518–520.
pubmed: 19650371
Moreira, A., Loquai, C., Pfohler, C., et al. (2019). Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. European Journal of Cancer (Oxford, England: 1990), 106, 12–23.
Fellner, A., Makranz, C., Lotem, M., et al. (2018). Neurologic complications of immune checkpoint inhibitors. Journal of Neuro-Oncology, 137, 601–609.
pubmed: 29332184
Astaras, C., de Micheli, R., Moura, B., Hundsberger, T., & Hottinger, A. F. (2018). Neurological adverse events associated with immune checkpoint inhibitors: Diagnosis and management. Current Neurology and Neuroscience Reports, 18, 3.
pubmed: 29392441
Thaipisuttikul, I., Chapman, P., & Avila, E. K. (2015). Peripheral neuropathy associated with ipilimumab: A report of 2 cases. Journal of Immunotherapy (Hagerstown, Md: 1997), 38, 77–79.
Wilgenhof, S., & Neyns, B. (2011). Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Annals of Oncology, 22, 991–993.
pubmed: 21357649
Dubey, D., David, W. S., Amato, A. A., et al. (2019). Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology, 93, e1093–ee103.
pubmed: 31405908
Gao, C. A., Weber, U. M., Peixoto, A. J., & Weiss, S. A. (2019). Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. Journal for Immunotherapy of Cancer, 7, 262.
pubmed: 31623673
pmcid: 6796437
Larkin, J., Chmielowski, B., Lao, C. D., et al. (2017). Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis. The Oncologist, 22, 709–718.
pubmed: 28495807
pmcid: 5469590
Altman, A. L., Golub, J. S., Pensak, M. L., & Samy, R. N. (2015). Bilateral facial palsy following Ipilimumab infusion for melanoma. Otolaryngology–Head and Neck Surgery, 153, 894–895.
pubmed: 26408564
Maurice, C., Schneider, R., Kiehl, T. R., et al. (2015). Subacute CNS demyelination after treatment with Nivolumab for melanoma. Cancer Immunology Research, 3, 1299–1302.
pubmed: 26419960
Garcia, C. R., Jayswal, R., Adams, V., Anthony, L. B., & Villano, J. L. (2019). Multiple sclerosis outcomes after cancer immunotherapy. Clinical & Translational Oncology, 21, 1336–1342.
Gettings, E. J., Hackett, C. T., & Scott, T. F. (2015). Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Multiple Sclerosis (Houndmills, Basingstoke, England), 21, 670.
Zafar, Z., Vogler, C., Hudali, T., & Bhattarai, M. (2019). Nivolumab-associated acute demyelinating encephalitis: A case report and literature review. Clinical Medicine & Research, 17, 29–33.
Cao, Y., Nylander, A., Ramanan, S., et al. (2016). CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology, 86, 1553–1556.
pubmed: 26984943
pmcid: 5573201
Nanda, R., Chow, L. Q., Dees, E. C., et al. (2016). Pembrolizumab in patients with advanced triple-negative breast Cancer: Phase Ib KEYNOTE-012 study. Journal of Clinical Oncology, 34, 2460–2467.
pubmed: 27138582
pmcid: 6816000
Bot, I., Blank, C. U., Boogerd, W., & Brandsma, D. (2013). Neurological immune-related adverse events of ipilimumab. Practical Neurology, 13, 278–280.
pubmed: 23487828
Touat, M., Talmasov, D., Ricard, D., & Psimaras, D. (2017). Neurological toxicities associated with immune-checkpoint inhibitors. Current Opinion in Neurology, 30, 659–668.
pubmed: 28938341
Schneider, S., Potthast, S., Komminoth, P., Schwegler, G., & Bohm, S. (2017). PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Reports in Oncology, 10, 473–478.
pubmed: 28626408
pmcid: 5471763
Lima, G., Kahn, A., Sama, S., & Savage, J. (2019). Aseptic meningitis as an immune-related adverse event after Pembrolizumab. Case Reports in Oncological Medicine, 2019, 2.
Toyozawa, R., Haratake, N., Toyokawa, G., et al. (2020). Atezolizumab-induced aseptic meningitis in patients with NSCLC. JTO Clinical and Research Reports, 1, 100012.
pubmed: 34589914
pmcid: 8474468
Kim, A., Keam, B., Cheun, H., Lee, S. T., Gook, H. S., & Han, M. K. (2019). Immune-checkpoint-inhibitor-induced severe autoimmune encephalitis treated by steroid and intravenous immunoglobulin. Journal of Clinical Neurology, 15, 259–261.
pubmed: 30877699
pmcid: 6444136
Hottinger, A. F., de Micheli, R., Guido, V., Karampera, A., Hagmann, P., & Du Pasquier, R. (2018). Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis. Neurology(R) Neuroimmunology & Neuroinflammation, 5, e439.
Chung, M., Jaffer, M., Verma, N., Mokhtari, S., Ramsakal, A., & Peguero, E. (2019). Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. Journal of Neurology.
Williams, T. J., Benavides, D. R., Patrice, K. A., et al. (2016). Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurology, 73, 928–933.
pubmed: 27271951
Wilson, R., Menassa, D. A., Davies, A. J., et al. (2018). Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Annals of Clinical and Translational Neurology, 5, 640–645.
pubmed: 29761126
pmcid: 5945956
Liao, B., Shroff, S., Kamiya-Matsuoka, C., & Tummala, S. (2014). Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology, 16, 589–593.
pubmed: 24482447
pmcid: 3956363
Abdel-Wahab, N., Shah, M., & Suarez-Almazor, M. E. (2016). Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLoS One, 11, e0160221.
pubmed: 27472273
pmcid: 4966895
Daxini, A., Cronin, K., & Sreih, A. G. (2018). Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clinical Rheumatology, 37, 2579–2584.
pubmed: 29923081
Lee, D. W., Santomasso, B. D., Locke, F. L., et al. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25, 625–638.
pubmed: 30592986
Santomasso, B. D., Park, J. H., Salloum, D., et al. (2018). Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discovery, 8, 958–971.
pubmed: 29880584
pmcid: 6385599
Park, J. H., Riviere, I., Gonen, M., et al. (2018). Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. The New England Journal of Medicine, 378, 449–459.
pubmed: 29385376
pmcid: 6637939
Lee, D. W., Gardner, R., Porter, D. L., et al. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124, 188–195.
pubmed: 24876563
pmcid: 24876563
Neelapu, S. S., Tummala, S., Kebriaei, P., et al. (2018). Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nature Reviews. Clinical Oncology, 15, 47–62.
pubmed: 28925994
Brahmer, J. R., Lacchetti, C., Schneider, B. J., et al. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 36, 1714–1768.
pubmed: 29442540
Karschnia, P., Jordan, J. T., Forst, D. A., et al. (2019). Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood, 133, 2212–2221.
pubmed: 30808634
Rubin, D. B., Danish, H. H., Ali, A. B., et al. (2019). Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain, 142, 1334–1348.
pubmed: 30891590
Teachey, D. T., Bishop, M. R., Maloney, D. G., & Grupp, S. A. (2018). Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit ‘ALL’. Nature Reviews Clinical Oncology, 15, 218.
pubmed: 29434335
Gust, J., Hay, K. A., Hanafi, L. A., et al. (2017). Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discovery, 7, 1404–1419.
pubmed: 29025771
pmcid: 5718945
Schuster, S. J., Svoboda, J., Chong, E. A., et al. (2017). Chimeric antigen receptor T cells in refractory B-cell lymphomas. The New England Journal of Medicine, 377, 2545–2554.
pubmed: 29226764
pmcid: 5788566
Torre, M., Solomon, I. H., Sutherland, C. L., et al. (2018). Neuropathology of a case with fatal CAR T-cell-associated cerebral edema. Journal of Neuropathology and Experimental Neurology, 77, 877–882.
pubmed: 30060228
Rubin, D. B., Al Jarrah, A., Li, K., et al. (2020). Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurology, 77, 1–7.
pmcid: 7418044
Neelapu, S. S. (2019). Managing the toxicities of CAR T-cell therapy. Hematological Oncology, 37(Suppl 1), 48–52.
pubmed: 31187535
Davila, M. L., Riviere, I., Wang, X., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 6, 224ra25.
pubmed: 24553386
pmcid: 4684949
Liu, S., Deng, B., Yin, Z., et al. (2020). Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 10, 15.
pubmed: 32029707
pmcid: 7005173
Gardner, R. A., Ceppi, F., Rivers, J., et al. (2019). Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood, 134, 2149–2158.
pubmed: 31697826
pmcid: 31697826
Taraseviciute, A., Tkachev, V., Ponce, R., et al. (2018). Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discovery, 8, 750–763.
pubmed: 29563103
pmcid: 6058704